201032793 六、發明說明： 【發明所屬之技術領域】 本發明係關於用於裝納組合物（比如含有活性藥劑（APA) 及類似物之組合物）之容器。 【先前技術】 某些含有具有活性藥劑之組合物之藥物產品，比如那些 液體或粉末之形式的藥物產品，可儲存於透明容器、白色 或不透明容器中。期望該藥物產品之使用者可以看見該容 # 器内部的内容物以決定剩餘量及是否有足夠組合物以投與 配藥。許多活性藥劑（APA)裝納於彩色玻璃容器或者不透 明塑膠容器中，這可能對於使用者決定其中所含APA化合 物之量造成困難。當含有該APA之該組合物係淺色或透明 色彩之液體時尤為有問題，當該組合物裝納於一透明容器 中時可能難以看清。 在淺色或透明容器中儲存含有APA之組合物亦可影響光 敏性APA，光敏性APA必須保存在一特定曝光量之下以防 ® 止降解或不必要的反應。特定地，某些含有APA之組合物 在暴露於來自光之紫外線之後可能會出現功效減弱、降解 產物增多或甚至完全喪失功效。將這些組合物裝納於遮蔽 該APA以免於暴露至光的容器係重要的。 ' 期望提供一種容器，若將含有APA之組合物裝鈉於其中 時，允許使用者有效且精確地看到該種組合物的含量，但 亦保護含有光敏性APA之組合物。 【發明内容】 144352.doc 201032793 在本發明之幾個態樣中提供用於裝納包括至少一種活性 藥劑之組合物的容器，該容器包括用於裝納該組合物之内 部，該組合物包括至少一種活性藥劑；具有内表面及外表 面之容器壁’丨中該内表面與該内部相連通；及視窗，該 視窗延伸貫穿該容器壁，以便容許從該容器之外看到該内 部；其中該容器壁包含著色劑以界定該内部中之背景，該 背景界定當透過視窗觀看時相對於該組合物的對比背景 幕。該組合物可為一淺色或透明液體。該組合物可包含至 少一種活性藥劑，比如糠酸莫米松（m〇metas〇ne fu_e)， 比如糠酸莫米松單水合物或無水糠酸莫米松、布地奈德 (budesonide)、金 # (m〇ntelukast)、經甲唑啉 (oxymetazoline)、氮卓斯汀（aze丨如丨㈣、糠酸氟替卡松 (咖咖_)、丙酸銳替卡松及組合或其醫藥上可接受之 鹽0 該外表面可包含鈦及/或至少一種選自由高密度聚乙 烯、聚丙歸H環烯烴共聚物及其組合所組成之群組 的材料。該内表面可包含選自由高密度聚乙烯聚丙烯、 聚s曰環稀煙共聚物及其組合所組成之群之—材料。該窗 口可包含選自由聚丙烯、環烯烴共聚物及其組合組成之群 之材料。特別可用於該“之材料係環稀烴共聚物。 組合物之容器’該組合物包括 其他實施例提供用於裝納 一内部區域，該内部區域 部表面之一底部；及從該 至少一種活性藥劑，該容器包括 包括一主體部；及具有一錐形内 主體部之底部延伸至該 主體部之頂端之視窗，該視窗允許 144352.doc 201032793 使用者看到該内部區域，其中該主體部包含著色劑，以便 在該内部區域界定背景，該背景界定在透過視窗觀看時相 對於組合物之對比背景幕。 再其他實施例提供包括一組合物之一藥物產品，該組合 物包括至少一種活性藥劑；用於裝納該組合物之内部；具 有-内表面及-外表®之一容器壁，纟十該内表面與該内 部相連通；及延伸貫穿該容器壁之視窗，以便容許從該容 0 器之外看到該内部，其中該容器壁包含一著色劑以便在該 内邛中界疋背景，該背景界定在透過視窗觀看時相對於組 合物之對比背景幕。該組合物可為一淺色或透明液體且該 組合物可包含至少一種光敏性活性藥劑，比如糠酸莫米 松，比如糠酸莫米松單水合物或無水糠酸莫米松、布地奈 德孟魯、幾甲唾琳、氮卓斯汀、糠酸氟替卡松、丙酸氟 替卡松及組合或其醫藥上可接受之鹽。該至少一種光敏性 活性藥劑可為糠酸莫米松，比如糠酸莫米松單水合物、孟 • 魯'羥甲唑啉'氮卓斯汀、糠酸氟替卡松、丙酸氟替卡松 及組合或其醫藥上可接受之鹽。 【實施方式】 本發明之幾個實施例參考圖式係指示一容器，該容器可 用於裝納液體，包含化學化合物，且特定地為含有ApA之 組合物。任一含有APA之組合物皆可裝納於該容器中且 特定地，該等含有APA之組合物可包含液體形式之ApA。 此外，該等含有APA之組合物可包含淺色或深色化合物， 或大體上透明之化合物。該含有APA之組合物可為一光敏 144352.doc 201032793 性化合物。如在此所使用，該術語「光敏性」可包含在有 光存在時會反應或降解之任一組合物，且特定地可包含在 紫外線存在時會反應之化合物，該術語「光敏性」不限於 在光存在時變得完全無效之化合物，且可包含在暴露於光 之後僅輕微反應及/或損失效力之化合物。 該組合物可為淺色或透明液體，且其可包含至少一種活 性藥劑，比如糠酸莫米松（比如糠酸莫米松單水合物或無 水糠酸莫米松）、布地奈德、孟魯、羥甲唑啉、氮卓斯 汀、糠酸氟替卡松、丙酸氟替卡松及其組合或醫藥上可接❹ ^:之鹽。光敏性化合物可適合於本發明之多樣實施例其 包含但不限於糠酸莫米松單水合物，其係在商標 NASONEX® 之下出售且由 Schedng c〇rp〇rati〇n 〇f201032793 VI. Description of the Invention: TECHNICAL FIELD OF THE INVENTION The present invention relates to a container for containing a composition such as a composition containing an active agent (APA) and the like. [Prior Art] Certain pharmaceutical products containing a composition having an active agent, such as those in the form of a liquid or powder, may be stored in a transparent container, a white or opaque container. It is expected that the user of the drug product will be able to see the contents of the container to determine the remaining amount and whether there is sufficient composition to administer the drug. Many active agents (APAs) are contained in colored glass containers or in opaque plastic containers, which may make it difficult for the user to determine the amount of APA compound contained therein. It is particularly problematic when the composition containing the APA is a liquid of a light or transparent color, which may be difficult to see when the composition is contained in a transparent container. The storage of APA-containing compositions in light or transparent containers can also affect photosensitivity APA, which must be stored at a specific exposure to prevent degradation or unwanted reactions. In particular, certain APA-containing compositions may experience reduced efficacy, increased degradation products, or even complete loss of efficacy upon exposure to ultraviolet light from light. It is important to incorporate these compositions into a container that shields the APA from exposure to light. It is desirable to provide a container which, when sodium is contained in a composition containing APA, allows the user to effectively and accurately see the content of the composition, but also protects the composition containing the photosensitive APA. SUMMARY OF THE INVENTION 144352.doc 201032793 A container for containing a composition comprising at least one active agent is provided in several aspects of the invention, the container comprising an interior for containing the composition, the composition comprising At least one active agent; a container wall having an inner surface and an outer surface, wherein the inner surface is in communication with the inner portion; and a window extending through the container wall to permit viewing of the interior from outside the container; The container wall contains a colorant to define a background in the interior that defines a contrasting backdrop relative to the composition when viewed through the window. The composition can be a light colored or clear liquid. The composition may comprise at least one active agent, such as mometasone furoate (m〇metas〇ne fu_e), such as mometasone furoate monohydrate or anhydrous mometasone furoate, budesonide, gold# (m) 〇ntelukast), oxymetazoline, azelastine (aze 丨 丨 (4), fluticasone citrate (caffe _), riticacin propionate and combinations thereof or a pharmaceutically acceptable salt thereof The outer surface may comprise titanium and/or at least one material selected from the group consisting of high density polyethylene, polypropylene H cycloolefin copolymers, and combinations thereof. The inner surface may comprise a polymer selected from the group consisting of high density polyethylene polypropylene, poly a material consisting of a group of s ring-rings and a combination thereof. The window may comprise a material selected from the group consisting of polypropylene, cyclic olefin copolymers, and combinations thereof, particularly useful for the "materials" Hydrocarbon copolymer. Container of composition 'The composition includes other embodiments for providing an inner region, one of the bottom surfaces of the inner region portion; and from the at least one active agent, the container including a body portion; And a bottom portion of a tapered inner body portion extending to a top end of the body portion, the window permitting a user to see the inner region, wherein the body portion includes a colorant to define a background in the inner region, The background defines a contrasting backdrop relative to the composition when viewed through the window. Still other embodiments provide a pharmaceutical product comprising a composition comprising at least one active agent; for containing the interior of the composition; - an inner surface and - one of the outer walls of the container, the inner surface being in communication with the inner portion; and a window extending through the wall of the container to permit viewing of the interior from outside the container, wherein the container wall A colorant is included to define a background in the inner ridge, the background defining a contrasting backdrop relative to the composition when viewed through the window. The composition can be a light colored or transparent liquid and the composition can comprise at least one Photosensitive active agents, such as mometasone furoate, such as mometasone furoate monohydrate or anhydrous mometasone furoate, budesonide montel, a few saliva , azelastine, fluticasone furoate, fluticasone propionate, and a combination thereof or a pharmaceutically acceptable salt thereof. The at least one photosensitive active agent may be mometasone furoate, such as mometasone furoate monohydrate, Meng Lu 'Oxymetazoline' azelastine, fluticasone citrate, fluticasone propionate, and combinations thereof or pharmaceutically acceptable salts thereof. [Embodiment] Several embodiments of the invention refer to a container indicating a container It can be used to contain a liquid, comprises a chemical compound, and is specifically a composition containing ApA. Any APA-containing composition can be contained in the container and, in particular, the APA-containing composition can comprise a liquid form. In addition, the APA-containing compositions may comprise a light or dark compound, or a substantially transparent compound. The APA-containing composition can be a photosensitive 144352.doc 201032793 compound. As used herein, the term "photosensitivity" may include any composition that will react or degrade in the presence of light, and specifically may include a compound that will react in the presence of ultraviolet light, the term "photosensitivity" not It is limited to compounds that become completely ineffective in the presence of light, and may include compounds that only slightly react and/or lose efficacy after exposure to light. The composition may be a light or transparent liquid, and it may comprise at least one active agent, such as mometasone furoate (such as mometasone furoate monohydrate or mometasone furoate), budesonide, monroe, hydroxy Moxazoline, azelastine, fluticasone citrate, fluticasone propionate, and combinations thereof or pharmaceutically acceptable salts of :. The photosensitizing compound may be suitable for various embodiments of the invention including, but not limited to, mometasone furoate monohydrate, sold under the trademark NASONEX® and by Schedng c〇rp〇rati〇n 〇f
Kenilworth, N.J.出售。光敏性化合物之另一實例為經甲唾 琳，其係在商標 AFRIN® 下由 Schering Corporation 〇f Kenilworth, N.J.出售。光敏性化合物之另一實例為糠酸氟 替卡松’其係在商標VERAMYST®下由GlaxoSmithKline出 f。 在此描述之容器可用於簡易地儲存該等含有Apa之組合 物’或其可與一遞送系統協力使用。該等遞送系統包含點 滴器、喷霧器、注射器及類似物。在此描述之該容器尤其 適於與鼻用分配裝置協力使用’然而應瞭解該容器可為任 一種類或形狀之容器，包含但不限於鼻用分配裝置。此種 類之鼻用分配器在此項技術中係熟知的。此種分配器之實 例呈現於例如美國專利第4,274,560號、第4,944,429號及第 144352.doc 201032793 5,433,343號；該等案之全部揭示内容以引用的方式併入本 文中。 參考圖1，提供一容器10,該容器10經設計以在其裏面 裝納含有APA之組合物。該含有APA之組合物可為彩色或 可為透明。在幾個實施例中，該含有APA之組合物係一淺 色或大體上透明之液體組合物。該容器1〇可為任何形狀， 包含圓筒、盒狀、無規則或任何其他所需之形狀。該容器 10包含一容器壁20 ’該容器壁20形成該組合物可被裝納之 ❹ 區域。該容器壁20可由任何所需之材料，包含玻璃或聚合 材料而製造》用於該容器壁20之適當的材料包含高密度聚 乙烯、聚丙烯、聚酯（比如PET、PETg)、COC及其他類似 材料。一般而言，期望使用一種可提供一較好水蒸氣壁 障’同時維持可接受之清晰度且不易碎的材料。該容器壁 2〇可由一聚合材料比如HDPE製造。 該容器10包含一頂部40及一底部50 ^該容器壁2〇及該底 φ 部50可作為分開塊而形成或作為一塊而形成。該容器1〇為 不漏流體的以確保裝納於其内之該APA組合物之安全與功 效係所需的。該容器壁20較好地對於其内部提供一色彩， 且更好地為不透明物。該容器壁20可包含一或多種著色劑 或遮光劑以提供該容器10之内部之彩色或不透明之樣式。 該容器壁20之該内部可為對比於裝納入其内之該含有ApA 之組合物之一色彩β藉由該術語「對比」，應瞭解該容器 壁20之該内部係足夠不同於該含有ΑΡΑ之組合物之色彩的 任何色彩。例如，該含有ΑΡΑ之組合物可為淺色或白色， 144352.doc 201032793 且該容器壁20之該内部可為深色。或者，該含有ApA之組 合物可為深色，且該容器壁2〇之該内部可為淺色或白色。 如在此所使用’該術語「深色」並非必然指代一黑色或類 似顏色。該術語「深色」指代比該APA之組合物或該容器 壁20之該内部深之色彩。對於輕淡色彩之ApA組合物，該 容器10之該内部可為任何更深的色彩，例如所期望之微紅 或褐色，且反之亦然。不管該含有APA之組合物是否是淺 色或深色’該容器壁20之該内部及該APA組合物應形成色 彩的對比。 該容器壁20包含至少-個視窗3〇,該視窗從約該底部區 域50延伸至約該頂部區域4〇。該視窗3〇係實質上透明，且 延伸貫穿該容器壁20之整個厚度，以便容許從該容器⑺之 外部觀看該等内容物。該視窗3〇具有一足夠的長度以允許 自外觀看裝納於該容器1〇内部60中含有APA之組合物之頂 部表面。該容器壁20及該視窗30可由相同材料製造，或其 等可由不同材料製造。例如，該視窗3〇可由單層或多層環 浠烴共聚物（(^(^、^^^、。(^、聚丙稀或其組合而製❿ 成。在一個實施例中，該視窗30係多層構造，該構造包含 多於一層材料。在其他實施例中，該視窗可由具有雙料覆 蓋成型PET層之COC而製成。 该谷益壁20及該視窗30可一起共模壓或可作為兩個分開 塊附接至一起。在一特定實施例中，該容器壁2〇可包含由 三層HDPE製成之外罩殼及由C0C製成之視窗3〇。在該實 施例中，使用之該等材料可自然地黏合到一起。在另一實 144352.doc 201032793 施例中，該容器壁20可由不透明標籤覆蓋，該標籤具有形 成該視窗30之敞開部。在其他實施例中，該容器壁2〇可包 含複數個具有形成該視窗30之澄清聚丙烯條的HDpE層。 如圖2中可見，該容器1〇包含具有一内部表面25及一外 部表面26之一容器壁20。該容器10包含—内部區域的，該 内部區域裝納該APA組合物。該容器1〇進—步包含一視窗 30 ’該視窗與該容器壁20一體地形成，該視窗可延伸至該 • 谷器壁之整個厚度（即從該内部表面25至該外部表面 26)。當該容器壁20之該内部表面25係不透明，使用者仍 可透過該視窗30觀看該容器1〇之該内部60。 在此種合併一視窗30之實施例中，該容器壁2〇之該内部 表面25可為一對比色彩及/或不透明壁，其阻擔實質量之 光進入該容器10之該内部60。如上文所解釋，該容器壁2〇 之該内部表面25及該内部60所裝納之該APA組合物應在顏 色上形成一對比《該容器壁20之該内部表面25可包含一或 φ 多種著色劑或遮光劑’以建立該容器壁20之對比的或不透 明的該内部表面25。加之’該容器壁20可包含一或多種 UV保護劑材料以進一步保護其内含有之含有該apa的組合 物。若需要，該容器壁20之該外部表面26可包含標記或其 他可識別其内含有之材料之記號。 併入對比色彩及/或不透明内部表面25於該容器1〇之該 内部60内建立陰影效應，在透過視窗3〇觀看時，該陰影效 應增加該APA組合物之能見度。這允許該使用者更清楚地 看到裝納於該容器10之内部60中的APA組合物，且更精確 144352.doc 201032793 地決定是否有足夠組合物以投與配藥，或是否應獲取更多 藥物。該視窗30可具有實質上比該容器壁20之整體圓周小 之寬度。特定地，該視窗30應具有比該容器壁20之整體圓 周小5%的寬度。 在裝納於該容器10中之該含有APA之組合物為光敏性的 實施例中’已發現只要該視窗30相對於該容器1〇具有小尺 度及厚度，就不會有過量光進入容器10。該視窗30之該整 體尺度（寬度、高度、厚度）連同其固有材料一起影響該視 窗30通過其傳輸光之能力。光敏性組合物之低度之曝光量 可能不會明顯或有害地減少此種光敏性組合物之效力。 該容器壁20之該内部表面25及該視窗30可在該容器1〇中 接觸到該含有APA之組合物。就此言之，期望此等組件係 由與該含有APA之組合物相容之材料製成，尤其應不含可 能損害該APA組合物之任何污染物。若需要，該容器丨〇可 包含一個或多個内襯層遮蓋該容器壁2〇之内部表面25及/ 或該視窗30。 參考圖3’其描寫該容器之一實施例’該容器包含多層 壁之配置。該多壁配置可使用於例如當所使用的著色劑或 遮光劑具有污染或以別的方式損害其所裝納之該Apa組合 物之可能時。在該實施例中，提供一容器丨丨〇，該容器J J 〇 具有多層以允許該APA化合物之能見性增高且同時保護内 容物以免被污染。該容器11〇可具有至少兩層或三層。該 容器110包含第一層112、第二層114及視情況第三層116。 若需要則可合併更多層。該第一層112位於最接近該容器 144352.doc -10· 201032793 110之該内部118，而該第二層114安置於進一步遠離該容 器110之該内部118的位置。該容器110可為任何形狀，包 含圓筒、盒狀、無規則或任何其他所需之形狀。該容器 110包含一内部區域118，其經配置以裝納該含有ApA之組 合物。該内部118(及其中所裝納之含APA組合物）可與第一 層112之内表面hi鄰近接觸。因此，該第—層112之該内 表面111應由對於該含有APA之組合物惰性的材料製造。 在一實施例中’該第一層112足夠透明以容許經過其而 觀看，且由不會污染該含有APA之組合物的惰性材料製 成。如上文描述之實施例，該第一層112可由塑膠、玻璃 或任何其他所需之材料而製造。用於該第—層112之適當 的材料包含HDPE、COC、聚丙烯、PET及其組合。由於該 第一層112與該含有apa之組合物接觸，其較佳係不包含 可能污染在其内裝納之該含有APA之組合物的任何材料。 該第二層114可含有光保護元件，且可由塑膠或其他材料 ❹ 製造。如上文描述之實施例，該第二層114可由塑膠、玻 璃或任何其他所需之材料而製造。用於該第二層114之適 當的材料包含HDPE、COC、聚丙烯、PET及其組合。該第 一層可包含一光保護材料，比如著色劑或uv保護劑材 料。在幾個實施例中，該第二層114係一對比色彩層及/或 不透明層，該層實質上限制光進入該容器之該内部118。 如上文所解釋，該術語「對比」指代與裝納於該容器ιι〇 之該内部11 8中之該組合物之色彩成對比的色彩。該第二 層114包含一内表面Π5及一外表面117。該第二層1丨4之該 144352.doc •11- 201032793 内表面115與該第一層112之該外表面113接觸。 該容器可為單層且可為深色以對於裝納在其中之該組合 物提供對比。 最後’若需要，該容器110可包含選用之第三層116。該 選用之第三層116可由任何所需之材料製成，且在一實施 例中由一塑膠材料製成，比如HDPE、COC、聚丙烯、PET 及其組合。該選用之第三層116包含一内表面119及一外表 面121。該第三層116之該内表面119與該第二層114之該外 表面117接觸。該第三層ι16之該外表面ι21暴露於該容器 110之外。雖然最期望該第三層116為透明，視使用者之偏 好而定，該第三層116可包括或不包含光保護材料或著色 劑。任何該等三層’包含該第一層112、該第二層ι14及該 選用之第二層116，皆可為任何色彩或具有任何不透明 度。在幾個實施例中’該等層112、U4、116中之至少一 者係足以與待裝納於其中之APA組合物成對比且/或充分不 透明以形成上文描述之對比效應。 包含該第一層112、該第二層114及該選用第三層116之 該等層可經由任何所需之處理程序而形成。在一實施例 中，該等層112、114、116係由塑膠製成且在上文描述之 該配置中共擠壓。照這樣，與該含有ApA之組合物接觸之 該第一層112避免與該第二層114形成之該著色劑材料之潛 在的瀝濾通過。在另一實施例中，各種層可分開形成且接 著施加於彼此。例如在一種形成方法中，可先形成該第一 層112，且將該第二層114接著施加於該第一層112之該外 144352.doc 12· 201032793 表面113上。類似地，若需要，該選用第三層116可接著施 加於該第二層114之該外表面117上。用以施加該等各種層 之任何方法均可使用。例如，該第二層丨14可糊料形式施 加於該第一層112之該外表面113，或其可以黏附物形式施 加於該第一層112之該外表面113上。類似地，該第三層 116可以糊料或黏附物形式施加於該第二層ι14之該外表面 117上。再一次按此方式’該第一層U2避免該第二層U4 之該光保護材料的潛在瀝濾通過。 ❹ 如圖4之描述，該多壁容器110可包含一窄視窗120，該 窄視窗延伸貫穿該容器11〇之各層112、114、116的至少一 部分，且允許該使用者從外面觀看該内部118。如上文所 解釋，該視窗120允許一陰影效應，讓使用者對於在該内 部118中之淺色内容物具有較清晰且更精確之視圖。該視 囪120可與層112、114、116—起一體成型，或視窗12〇可 為一分開塊且裝入該容器110中。該視窗12〇可由任何材料 ❼ 製成。在一實施例中該視窗12 0由一聚合材料製成，比如 HDPE、COC、聚丙烯、PET及其組合。該視窗12〇之該内 表面122可與該内部118接觸，且因此可與裝納在其中之該 含有APA之組合物接觸。因此，為避免該含有apa之組合 物的污染，該視窗120應由一惰性材料製成，或其應沒有 污染物》 在各種之實施例中，該視窗120延伸貫穿該容器之每一 層’使得使用者可透過外部觀看内部118。該視窗12〇可為 任何形狀或設計’包含直鏈、圓周、盒狀、曲線、無規則 144352.doc •13- 201032793 或任何其他允許通過該視窗120觀看之所需形狀。較好 地，該視窗120位於接近該容器11〇底部之一位置，以致使 該使用者可觀看該容器110中含有的任何内容物之低量。 該視窗120可具有足夠長度以允許觀看裝納於該容器ιι〇之 該内部118中之該含有ΑΡΑ之組合物的頂面。因為可觀看 該含有ΑΡΑ之組合物的該頂面之能力，故可有效地估計該 含有ΑΡΑ之組合物的量。由於該容器11〇包含該視窗12〇， 使用者可在不需要打開該容器11〇且未使該含有ΑρΑ之組 合物暴露至該容器110之外潛在有害元素的前提下觀看該 容器110中之内容物。 在該等收納視窗之實施例中，任何該等層，包含該第一 層112、該第二層114及/或該第三層U6皆可為上文所描述 之對比色彩層，其將阻擋一實質量的光進入該容器η〇之 該内部118中。該第二層114可為對比色彩及/或不透明 層。第二層114可為不透明，因此阻擋所有之光不讓其通 過。該第二層114可包含一或多種著色劑或遮光劑，以建 立該對比或不透明之第二層114。加之，該第二層114可包 含一或多種UV保護劑材料以進一步保護其中所裝納的含 有ΑΡΑ之組合物。 如上文所解釋，併入與該視窗12〇協力之對比色彩或不 透明層，在該容器110之該内部118中建立一陰影，該陰影 增加透過該透明視窗120觀看其中所裝納之含有ΑρΑ之組 »物的可見度。此允許使用者更清晰地看到該容器11〇之 該内部118，且更精確地確定是否有足夠白色或淺色之含 144352.doc • 14- 201032793 有APA之組合物可投藥，或是否應獲得更多。 該容器110可包含施加於該等三層112、114、116之任何 表面上之一或多種UV保護劑材料。UV保護劑材料之使用 在當裝納於該容器110中之該含有APA之組合物係一光敏 性組合物時係有用的。該uv保護劑材料可在任何時間施 加於該等表面112、114、116上，且可以任何所需之形式 施加，包含藉由喷霧、擠壓、浸潰、塗布或其他類似方 法。 在此描述之本發明可進一步包含出入口及/或遞送系 統。此實施例可用於上文描述之該單壁或多壁設計中。僅 出於描寫之目的將參考該多壁容器11〇，唯應瞭解在此描 述之該等實施例可用於上文描述之單壁容器1〇。該容器 110可包含出入口，該出入口提供進入内罩殼110之該内部 118的進口。該出入口通常被覆蓋，使得無法移除該含有 APA之組合物’除非使用者手動操縱容器丨1〇以移除該含 有APA之組合物。 在一實施例中，如上文所解釋之分配（例如鼻分配器）或 滴落機構可裝入該容器110，以便具有經由該出入口通達 該内部118之進口。在該構造中可有一鼻分配器與該容器 110之該内部118相連通。該分配器可經配置以促使幾劑量 之該含有APA之組合物從該内部U8且進入該使用者之鼻 腔。該分配器及該容器11〇共同界定用於分配幾劑量液髖 至使用者鼻腔之裝置。在其他實施例中，該容器110可包 含一蓋子或其他機構以允許使用者將該容器11〇之該内部 144352.doc •15- 201032793 118封鎖起來（例如封鎖該出入口）。 在一些實施例中，該容器11 〇可與雙組件系統協力使 用。例如，該系統可包含多重罩殼，其中本發明之該容器 110形成該内罩殼，且因此裝納該含有APA之組合物，且 具有包圍該内罩殼之一分開的外罩殼。 在另一實施例中，一容器具有一錐形底部以減少過剩 APA的量。如圖5及圖6所描述，提供具有一内部215之一 容器200，該容器設計以用於裝納一含有APA之組合物 240。該含有APA之組合物240可為液體的形式，但可預期 其他形式，比如粉末。該容器200包含一主體部21〇及一基 部230。該主體部210及該基部230可由相同材料或不同材 料製造，其可包含與裝納在其中之該含有APA之組合物 240相容的任何材料。該主體部210及該基部230可由聚合 材料製成’比如HDPE、COC、聚丙烯及其組合物。該主 體部210及該基部230可為彩色的或其等可為透明的。在— 實施例中’該主體部210與該基部230係對比於裝納在其中 之該組合物的顏色，且可為不透明。使用上文描述之該等 容器’該容器200可包含在其本髏上指示裝納在其中之内 容物的標記。 該主體部210與該基部230可一起形成為單塊模壓單元， 或其等可形成為分開模壓塊且裝在一起。熟習此項技術者 應瞭解’考慮到該容器200之每個部分的組件，以分開塊 形式形成該主體部210及該基部230可提供明顯的製造優 勢。5亥主體部210及該基部230可由任何已知方法附接在一 144352.doc •16· 201032793 起’包含藉由超音波焊接法、機械附接、黏合劑或其他所 需之方法。當裝在一起時，該主體部21〇及該基部23〇形成 整體連接的容器200’該容器係不漏流體地以安全且有效 地在其内裝納該含有Apa之組合物。 該主體部210包含一可見視窗22〇，該視窗允許使用者觀 看邊谷器200之該内部215之内容物。該視窗220可為立式 條紋的形式’然而可預期其他幾個構造，包含橢圓、方塊 或其他所需之輪廓。該視窗220可安置於該主體部210之任 何側面’包含前面、後面及侧面。若需要，可在該主體部 210上安置多於一個視窗22〇。期望該視窗22〇具有相對薄 之尺寸’當允許該主體部210形成該容器200主體之大部分 時，允許觀看該容器200中之内容物。在一實施例中，該 視窗220之厚度小於該容器200主體之圓周之約5%。該視 窗220可具有任何所需之長度，且在一實施例中，該視窗 始於或接近該基部230與該主體部210連接之位置。該視窗 φ 220可具有一足夠長度，使其在或接近該主體部210之頂端 延伸。在一實施例中，該容器220主體包含施加於該外表 面之一標籤或黏附物，該標籤足夠不透明或對比色彩且進 一步包含作為該標籤之一部分的視窗220。 在一特定實施例中，如圖6中可見，該基部230包含一錐 形底端235。該錐形底端235可盡可能如所需般朝該内部 215延伸。該錐形底端235可大約延伸至該基部230與該主 體部210連接之區域。該含有APA之組合物240係裝納於該 容器200之該内部215中，且進一步含於由該基部230之該 144352.doc 201032793 錐形底端235形成之區域中。 該基部230之該錐形底端235有用於減少在使用者認為該 容器200用盡之後可能殘留於容器2〇〇中之含有ApA的組合 物240的過剩量。此配置尤其可使用於有遞送系統（圖中未 呈現）附接於該容器200時，且特別可使用於該遞送系統包 含喷霧附件時。在典型喷霧瓶配置中，該遞送系統包含延 伸至該容器内的軟管。該軟管通常不能有效移除遺留在該 谷器最底端之該組合物。使用底端係平的典型配置，其會 留下殘留過量組合物之大量區域。在一些實例中，已發現❹ 該種典型容器中可能殘留有足以投與多達8至1〇個劑量之 組合物保持未使用。 相反地，利用本發明之該錐形底端235，該基區23〇在該 容器200之該内部215中提供更少區域，且因此大大減少在 使用後遺留於該容器200内之含有ApA之組合物24〇的量。 實際上，已確定通常在該容器2〇〇中殘留足以提供約24個 劑量的組合物240未使用。在此提供之本發明因此將含有 APA之組合物240的浪費量減少成先前技藝裝置的約25%。⑩ 此外，該視窗220可經配置成僅延伸至該錐形底端235之頂 端，以使使用者不會發覺殘留少量的組合物24〇,因此當 組合物240之量不足夠高至到達該遞送系統時將不會嘗試 提供劑量。 已提出本發明之實施例之描述来作闡釋及描述用。其等 不意欲遺漏或限制本發明至精確形式的揭示，且顯然地根 據上述教示可作出許多修正及變更。 144352.doc -18- 201032793 【圖式簡單說明】 圖1係根據本發明之一所形成之容器的一實施例。 圖2係圖1之一容器之一橫截面視圖。 圖3係根據本發明之第二實施例之所形成之一容器的一 橫截面視圖。 圖4係根據本發明之第二實施例之所形成之一具有一視 窗之容器的一橫截面視圖。 圖5係根據本發明之另一實施例之所形成之一容器的一 側面圖。 圖6係圖5之一容器之一橫截面視圖。 【主要元件符號說明】 10 容器 20 容器壁 25 内部表面 26 外部表面 30 视窗 40 頂部 50 底部 60 内部區域 110 容器 111 内表面 112 第一層 113 夕卜表面 114 $二層 144352.doc •19- 201032793 115 内表面 116 選用第三層 117 外表面 118 内部 119 内表面 120 視窗 121 外表面 122 内表面 200 容器 210 主體部 215 内部 220 視窗 230 基部 235 錐形底端 240 含有APA之組合物 144352.doc -20-Sold by Kenilworth, N.J. Another example of a photosensitive compound is vial, which is sold under the trademark AFRIN® by Schering Corporation 〇f Kenilworth, N.J. Another example of a photosensitive compound is fluticasone citrate, which is produced by GlaxoSmithKline under the trademark VERAMYST®. The containers described herein can be used to easily store such Apa containing compositions' or they can be used in conjunction with a delivery system. Such delivery systems include droppers, nebulizers, syringes, and the like. The container described herein is particularly suitable for use in conjunction with a nasal dispensing device. It should be understood, however, that the container can be any type or shape of container, including but not limited to nasal dispensing devices. Such nasal dispensers are well known in the art. An example of such a dispenser is disclosed in, for example, U.S. Patent Nos. 4,274,560, 4,944,429, and 144, 352, filed to s. Referring to Figure 1, a container 10 is provided which is designed to contain a composition containing APA therein. The APA-containing composition can be colored or can be transparent. In several embodiments, the APA-containing composition is a light or substantially transparent liquid composition. The container 1 can be of any shape, including a cylinder, a box, a random or any other desired shape. The container 10 includes a container wall 20' which defines a region in which the composition can be contained. The container wall 20 can be made of any desired material, including glass or polymeric materials. Suitable materials for the container wall 20 include high density polyethylene, polypropylene, polyester (such as PET, PETg), COC, and others. Similar materials. In general, it is desirable to use a material that provides a better water vapor barrier while maintaining acceptable clarity and is not brittle. The container wall 2 can be made of a polymeric material such as HDPE. The container 10 includes a top portion 40 and a bottom portion 50. The container wall 2 and the bottom portion 50 are formed as separate pieces or formed as one piece. The container 1 is fluid-tight to ensure the safety and efficacy of the APA composition contained therein. The container wall 20 preferably provides a color to its interior, and is preferably an opaque material. The container wall 20 can contain one or more coloring agents or opacifiers to provide a color or opaque pattern of the interior of the container 10. The interior of the container wall 20 can be "contrast" with respect to the color β of one of the compositions containing the ApA contained therein, and it should be understood that the interior of the container wall 20 is sufficiently different from the containing Any color of the color of the composition. For example, the composition containing bismuth may be light or white, 144352.doc 201032793 and the interior of the container wall 20 may be dark. Alternatively, the composition containing ApA may be dark, and the interior of the container wall 2 may be light or white. As used herein, the term "dark" does not necessarily refer to a black or similar color. The term "dark" refers to a darker color than the composition of the APA or the interior of the container wall 20. For a light-colored ApA composition, the interior of the container 10 can be any deeper color, such as the desired reddish or brown color, and vice versa. Regardless of whether the APA-containing composition is light or dark, the interior of the container wall 20 and the APA composition should form a color contrast. The container wall 20 includes at least a window 3 that extends from about the bottom region 50 to about the top region 4A. The window 3 is substantially transparent and extends throughout the thickness of the container wall 20 to permit viewing of the contents from the exterior of the container (7). The window 3 has a length sufficient to allow for viewing from the outside the top surface of the composition containing the APA contained in the interior 60 of the container. The container wall 20 and the window 30 can be made of the same material, or the like can be made of different materials. For example, the window 3 can be made of a single or multiple layers of a cyclic hydrocarbon copolymer ((^, ^^^, (^, polypropylene, or a combination thereof). In one embodiment, the window 30 is A multi-layer construction comprising more than one layer of material. In other embodiments, the window may be made of a COC having a dual-cover overmolded PET layer. The valley wall 20 and the window 30 may be co-molded together or may serve as two separate blocks. Attached together, in a particular embodiment, the container wall 2 can comprise an outer casing made of three layers of HDPE and a window 3 made of COS. In this embodiment, the materials used can be Naturally bonded together. In another embodiment 144352.doc 201032793, the container wall 20 may be covered by an opaque label having an open portion forming the window 30. In other embodiments, the container wall 2 may be A plurality of HDpE layers having clarified polypropylene strips forming the window 30. As can be seen in Figure 2, the container 1 includes a container wall 20 having an interior surface 25 and an exterior surface 26. The container 10 includes - interior Regional, this internal area An APA composition. The container 1 includes a window 30' that is integrally formed with the container wall 20, the window extending to the entire thickness of the wall of the bar (ie, from the interior surface 25 to the exterior) Surface 26). When the interior surface 25 of the container wall 20 is opaque, the user can still view the interior 60 of the container through the window 30. In such an embodiment incorporating a window 30, the container wall The inner surface 25 can be a contrasting color and/or opaque wall that resists substantial quality light entering the interior 60 of the container 10. As explained above, the inner surface 25 of the container wall 2 The APA composition contained within the interior 60 should form a contrast in color "the inner surface 25 of the container wall 20 can comprise one or more than a plurality of colorants or opacifiers" to establish a contrast of the container wall 20 or The inner surface 25 is opaque. In addition, the container wall 20 can comprise one or more UV protectant materials to further protect the composition containing the apa contained therein. If desired, the outer surface 26 of the container wall 20 can comprise Mark or other A mark of the material contained therein. Incorporating a contrasting color and/or opaque inner surface 25 creates a shadow effect within the interior 60 of the container 1 , which increases the APA composition as viewed through the window 3〇 Visibility. This allows the user to more clearly see the APA composition contained in the interior 60 of the container 10, and more accurately 144352.doc 201032793 to determine if there is sufficient composition to dispense the drug, or whether it should More medication is obtained. The window 30 can have a width that is substantially smaller than the overall circumference of the container wall 20. Specifically, the window 30 should have a width that is 5% less than the overall circumference of the container wall 20. In the embodiment in which the APA-containing composition contained in the container 10 is photosensitive, it has been found that as long as the window 30 has a small size and thickness relative to the container 1 , no excess light enters the container 10 . . The overall dimensions (width, height, thickness) of the window 30, along with its intrinsic material, affect the ability of the window 30 to transmit light therethrough. The low exposure of the photosensitive composition may not significantly or detrimentally reduce the effectiveness of such photosensitive compositions. The inner surface 25 of the container wall 20 and the window 30 can contact the APA-containing composition in the container 1A. In this regard, it is desirable that such components be made of materials compatible with the APA-containing composition, and in particular, free of any contaminants that may damage the APA composition. If desired, the container 丨〇 may include one or more inner liners covering the interior surface 25 of the container wall 2 and/or the window 30. Referring to Figure 3', an embodiment of the container is depicted. The container comprises a multi-walled configuration. The multi-wall configuration can be used, for example, when the coloring agent or sunscreen used is contaminating or otherwise damaging the Apa composition to which it is contained. In this embodiment, a container 提供 is provided having a plurality of layers to allow for increased visibility of the APA compound while protecting the contents from contamination. The container 11 can have at least two or three layers. The container 110 includes a first layer 112, a second layer 114, and optionally a third layer 116. More layers can be combined if needed. The first layer 112 is located closest to the interior 118 of the container 144352.doc -10· 201032793 110, and the second layer 114 is disposed further away from the interior 118 of the container 110. The container 110 can be of any shape, including a cylinder, a box, a random or any other desired shape. The container 110 includes an interior region 118 that is configured to contain the composition containing the ApA. The inner portion 118 (and the APA-containing composition contained therein) can be in adjacent contact with the inner surface hi of the first layer 112. Thus, the inner surface 111 of the first layer 112 should be made of a material that is inert to the APA-containing composition. In one embodiment, the first layer 112 is sufficiently transparent to allow viewing therethrough and is made of an inert material that does not contaminate the APA-containing composition. In the embodiment described above, the first layer 112 can be made of plastic, glass or any other desired material. Suitable materials for the first layer 112 include HDPE, COC, polypropylene, PET, and combinations thereof. Since the first layer 112 is in contact with the apa-containing composition, it preferably does not contain any material that may contaminate the APA-containing composition contained therein. The second layer 114 can contain photoprotective elements and can be fabricated from plastic or other materials. In the embodiment described above, the second layer 114 can be made of plastic, glass or any other desired material. Suitable materials for the second layer 114 include HDPE, COC, polypropylene, PET, and combinations thereof. The first layer may comprise a photoprotective material such as a color former or a uv protectant material. In several embodiments, the second layer 114 is a contrasting color layer and/or an opaque layer that substantially restricts light from entering the interior 118 of the container. As explained above, the term "contrast" refers to a color that is contrasted with the color of the composition contained in the interior 11 of the container ιι. The second layer 114 includes an inner surface crucible 5 and an outer surface 117. The inner surface 115 of the second layer 1 丨 4 144352.doc • 11- 201032793 is in contact with the outer surface 113 of the first layer 112. The container can be a single layer and can be dark to provide contrast for the composition contained therein. Finally, the container 110 can include an optional third layer 116 if desired. The optional third layer 116 can be made of any desired material and, in one embodiment, is made of a plastic material such as HDPE, COC, polypropylene, PET, and combinations thereof. The optional third layer 116 includes an inner surface 119 and an outer surface 121. The inner surface 119 of the third layer 116 is in contact with the outer surface 117 of the second layer 114. The outer surface ι21 of the third layer ι16 is exposed outside the container 110. While it is most desirable for the third layer 116 to be transparent, depending on the user's preference, the third layer 116 may or may not include a photoprotective material or colorant. Any of the three layers ' comprising the first layer 112, the second layer ι 14 and the optional second layer 116 can be of any color or have any opacity. In several embodiments, at least one of the layers 112, U4, 116 is sufficient to contrast and/or be sufficiently opaque to the APA composition to be contained therein to form the contrast effect described above. The layers comprising the first layer 112, the second layer 114 and the optional third layer 116 can be formed via any desired processing procedure. In one embodiment, the layers 112, 114, 116 are made of plastic and are coextruded in the configuration described above. As such, the first layer 112 in contact with the ApA-containing composition avoids the potential leaching of the colorant material formed by the second layer 114. In another embodiment, the various layers may be formed separately and applied to each other. For example, in one method of formation, the first layer 112 can be formed first, and the second layer 114 can then be applied to the outer surface 144352.doc 12· 201032793 surface 113 of the first layer 112. Similarly, the optional third layer 116 can then be applied to the outer surface 117 of the second layer 114, if desired. Any method for applying the various layers can be used. For example, the second layer 14 can be applied to the outer surface 113 of the first layer 112 in a paste form, or it can be applied to the outer surface 113 of the first layer 112 in the form of an adhesive. Similarly, the third layer 116 can be applied to the outer surface 117 of the second layer ι 14 in the form of a paste or adhesive. Again in this manner, the first layer U2 avoids the potential leaching of the photoprotective material of the second layer U4. As illustrated in FIG. 4, the multi-walled container 110 can include a narrow window 120 that extends through at least a portion of each of the layers 112, 114, 116 of the container 11 and allows the user to view the interior 118 from the outside. . As explained above, the window 120 allows for a shadowing effect that gives the user a clearer and more accurate view of the lighter content in the interior 118. The baffle 120 can be integrally formed with the layers 112, 114, 116, or the window 12 can be a separate block and loaded into the container 110. The window 12 can be made of any material ❼. In one embodiment the window 120 is made of a polymeric material such as HDPE, COC, polypropylene, PET, and combinations thereof. The inner surface 122 of the window 12 can be in contact with the inner portion 118 and thus can be in contact with the APA-containing composition contained therein. Thus, to avoid contamination of the apa containing composition, the window 120 should be made of an inert material, or it should be free of contaminants. In various embodiments, the window 120 extends through each layer of the container. The user can view the interior 118 through the outside. The window 12 can be any shape or design 'contains straight chain, circumference, box shape, curve, irregular 144352.doc • 13- 201032793 or any other desired shape that allows viewing through the window 120. Preferably, the window 120 is located adjacent one of the bottoms of the container 11 such that the user can view a low amount of any content contained in the container 110. The window 120 can be of sufficient length to permit viewing of the top surface of the composition containing the crucible contained within the interior 118 of the container. Since the ability to view the top surface of the composition of the crucible can be viewed, the amount of the composition containing the crucible can be effectively estimated. Since the container 11 includes the window 12, the user can view the container 110 without opening the container 11 and exposing the composition containing the ΑρΑ to a potentially harmful element other than the container 110. Content. In any of the embodiments of the receiving window, any of the layers, including the first layer 112, the second layer 114, and/or the third layer U6 may be the contrast color layer described above, which will block A substantial amount of light enters the interior 118 of the container η. The second layer 114 can be a contrasting color and/or an opaque layer. The second layer 114 can be opaque, thus blocking all light from passing through. The second layer 114 can include one or more coloring agents or opacifiers to create the second layer 114 of the contrast or opacity. Additionally, the second layer 114 can comprise one or more UV protectant materials to further protect the enamel-containing composition contained therein. As explained above, incorporating a contrasting color or opaque layer in conjunction with the window, a shadow is created in the interior 118 of the container 110, the shadow increasing through the transparent window 120 to view the contents contained therein. Group» visibility of the object. This allows the user to see the inner portion 118 of the container 11 more clearly and more accurately determine if there is enough white or light color containing 144352.doc • 14- 201032793 A composition of APA can be administered, or should Get more. The container 110 can comprise one or more UV protectant materials applied to any of the three layers 112, 114, 116. The use of a UV protectant material is useful when the APA-containing composition contained in the container 110 is a photosensitive composition. The uv protectant material can be applied to the surfaces 112, 114, 116 at any time and can be applied in any desired form, including by spraying, extrusion, dipping, coating or the like. The invention described herein may further comprise an access and/or delivery system. This embodiment can be used in the single wall or multi-wall design described above. The multi-walled container 11 will be referred to for purposes of illustration only, and it should be understood that the embodiments described herein can be used with the single wall container 1 described above. The container 110 can include an access opening that provides access to the interior 118 of the inner casing 110. The access is typically covered so that the APA-containing composition cannot be removed' unless the user manually manipulates the container to remove the APA-containing composition. In one embodiment, the dispensing (e.g., nasal dispenser) or drip mechanism as explained above can be loaded into the container 110 to have access to the interior 118 via the access opening. In this configuration a nasal dispenser can be in communication with the interior 118 of the container 110. The dispenser can be configured to cause several doses of the APA-containing composition to pass from the interior U8 and into the nasal cavity of the user. The dispenser and the container 11" together define a means for dispensing a few doses of liquid hips to the user's nasal cavity. In other embodiments, the container 110 can include a lid or other mechanism to allow a user to lock the interior 144352.doc • 15-201032793 118 of the container 11 (e.g., to block the access). In some embodiments, the container 11 can be used in conjunction with a two-component system. For example, the system can include multiple enclosures in which the container 110 of the present invention forms the inner casing and thus houses the APA-containing composition and has a separate outer casing surrounding the inner casing. In another embodiment, a container has a tapered bottom to reduce the amount of excess APA. As depicted in Figures 5 and 6, a container 200 is provided having an interior 215 that is designed to contain a composition 240 containing APA. The APA-containing composition 240 can be in the form of a liquid, but other forms, such as a powder, are contemplated. The container 200 includes a body portion 21A and a base portion 230. The body portion 210 and the base portion 230 can be made of the same material or different materials, and can comprise any material that is compatible with the APA-containing composition 240 contained therein. The body portion 210 and the base portion 230 can be made of a polymeric material such as HDPE, COC, polypropylene, and combinations thereof. The body portion 210 and the base portion 230 can be colored or the like can be transparent. In the embodiment, the body portion 210 and the base portion 230 are compared to the color of the composition contained therein, and may be opaque. Using the containers described above, the container 200 can include indicia indicating the contents contained therein on its base. The body portion 210 and the base portion 230 may be formed together as a single-piece molding unit, or the like may be formed as separate molded blocks and assembled together. Those skilled in the art will appreciate that the formation of the body portion 210 in a separate block and the base portion 230 can provide significant manufacturing advantages in view of the components of each portion of the container 200. The 5 hull body portion 210 and the base portion 230 can be attached by any known method to include a method of ultrasonic welding, mechanical attachment, adhesive, or the like as required by a method of 144352.doc •16·201032793. When assembled together, the body portion 21 and the base portion 23 form an integrally connected container 200' which is fluid-tight to safely and efficiently contain the Apa-containing composition therein. The body portion 210 includes a visible window 22 that allows the user to view the contents of the interior 215 of the edge barner 200. The window 220 can be in the form of a vertical stripe' however several other configurations are contemplated, including elliptical, square or other desired contours. The window 220 can be disposed on any side of the body portion 210 including front, back and sides. More than one window 22 can be placed on the body portion 210 if desired. It is desirable that the window 22 has a relatively thin size' allowing viewing of the contents of the container 200 when the body portion 210 is allowed to form a substantial portion of the body of the container 200. In one embodiment, the window 220 has a thickness that is less than about 5% of the circumference of the body of the container 200. The window 220 can have any desired length, and in one embodiment, the window begins or approximates the location at which the base 230 is coupled to the body portion 210. The window φ 220 may have a length sufficient to extend at or near the top end of the body portion 210. In one embodiment, the body of the container 220 includes a label or adhesive applied to the outer surface that is sufficiently opaque or contrasting in color and further includes a window 220 that is part of the label. In a particular embodiment, as seen in Figure 6, the base 230 includes a tapered bottom end 235. The tapered bottom end 235 can extend toward the interior 215 as much as desired. The tapered bottom end 235 can extend approximately to the area where the base 230 is coupled to the body portion 210. The APA-containing composition 240 is contained within the interior 215 of the container 200 and is further contained in the region formed by the tapered end 235 of the base 230 of the 144352.doc 201032793. The tapered bottom end 235 of the base 230 has an excess amount for reducing the composition of the ApA-containing composition 240 that may remain in the container 2 after the user believes that the container 200 has been used up. This configuration can be used, inter alia, when a delivery system (not shown) is attached to the container 200, and particularly when the delivery system includes a spray attachment. In a typical spray bottle configuration, the delivery system includes a hose that extends into the container. The hose typically does not effectively remove the composition left at the bottom end of the bar. A typical configuration with a flat bottom is used which leaves a large area of residual excess composition. In some instances, it has been discovered that a composition sufficient to administer up to 8 to 1 dose of this composition may remain unused in such a typical container. Conversely, with the tapered bottom end 235 of the present invention, the base region 23 provides less area in the interior 215 of the container 200, and thus greatly reduces the inclusion of ApA remaining in the container 200 after use. The amount of composition 24 〇. In fact, it has been determined that the composition 240, which is typically sufficient to provide about 24 doses in the container 2, is not used. The invention provided herein thus reduces the amount of waste of the APA containing composition 240 to about 25% of prior art devices. In addition, the window 220 can be configured to extend only to the top end of the tapered bottom end 235 so that the user does not notice a small amount of composition 24 〇 remaining, so when the amount of the composition 240 is not high enough to reach the Do not attempt to provide a dose when delivering the system. The description of the embodiments of the invention has been presented for purposes of illustration and description. The invention is not intended to be exhaustive or to limit the scope of the present invention. 144352.doc -18- 201032793 BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is an embodiment of a container formed in accordance with one of the present invention. Figure 2 is a cross-sectional view of one of the containers of Figure 1. Figure 3 is a cross-sectional view of a container formed in accordance with a second embodiment of the present invention. Figure 4 is a cross-sectional view of a container having a window formed in accordance with a second embodiment of the present invention. Figure 5 is a side elevational view of one of the containers formed in accordance with another embodiment of the present invention. Figure 6 is a cross-sectional view of one of the containers of Figure 5. [Main component symbol description] 10 Container 20 Container wall 25 Internal surface 26 External surface 30 Window 40 Top 50 Bottom 60 Internal area 110 Container 111 Inner surface 112 First layer 113 表面布 surface 114 $2 layer 144352.doc •19- 201032793 115 Inner surface 116 optional third layer 117 outer surface 118 inner 119 inner surface 120 window 121 outer surface 122 inner surface 200 container 210 body portion 215 inner 220 window 230 base 235 tapered bottom end 240 composition containing APA 144352.doc - 20-